Merus N.V.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jan van de Winkel
- Full Time Employees
- 260
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Yalelaan 62 Utrecht Netherlands 3584 CM
- IPO Date
- May 19, 2016
- CIK
- 0001651311
- Website
- merus.nl
- Similar Companies
- Business
- Merus N.V. is a clinical-stage immuno-oncology company focused on the development of bispecific and trispecific antibody therapeutics for the treatment of cancer. The company specializes in its proprietary Biclonics® technology platform that produces full-length human bispecific antibodies designed to simultaneously engage multiple cancer targets, thereby activating the immune system to kill tumor cells while also inhibiting tumor growth pathways. Its core product pipeline includes Zenocutuzumab (BIZENGRI®), approved by the U.S. FDA for NRG1 fusion-positive pancreatic adenocarcinoma and non-small cell lung cancer; Petosemtamab, a bispecific antibody targeting epidermal growth factor receptor (EGFR) and LGR5, in development for head and neck as well as colorectal cancers; MCLA-158, MCLA-129, ONO-4685, and INCA33890, which are in various stages of clinical trials targeting solid tumors, T cell lymphoma, and other cancers. Merus operates primarily out of its headquarters in Utrecht, the Netherlands, with additional offices in the United States and collaborative partnerships worldwide. Founded in 2003, the company has established significant collaboration agreements with pharmaceutical companies including Eli Lilly, Ono Pharmaceutical, and Betta Pharmaceuticals. In the last two years, Merus has undergone notable strategic developments including FDA accelerated approval and breakthrough therapy designation for key candidates, initiation of multiple Phase 2 and 3 clinical trials, and expanded its antibody therapeutic pipeline. In late 2025, Merus announced a major acquisition agreement by Genmab valued at approximately $8 billion, representing a significant corporate milestone and expected to close in early 2026. The company’s products and services directly serve the oncology and biotechnology sectors, targeting patients with advanced cancers by developing innovative immuno-oncology therapies that harness the immune system's capacity to address unmet medical needs. Merus continues to focus on advancing its differentiated bispecific antibody platforms (Biclonics® and Multiclonics®) across rare and difficult-to-treat cancer indications with the objective of improving therapeutic outcomes through novel mechanisms of action and targeted immune activation. This includes the commercialization potential of its FDA-approved products and ongoing clinical advancements aiming to broaden its therapeutic reach globally.
LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update
Merus Power Delivers an Energy Storage System for Extreme Arctic Conditions
Federated Hermes Inc. Sells 279,425 Shares of Merus N.V. $MRUS
Merus N.V. (NASDAQ:MRUS) Receives Average Recommendation of “Hold” from Analysts
Market Today: Tesla dethroned; Wall St. starts 2026 higher
First Look: Futures Climb, FTSE 10,000, BYD Tops Tesla
First Look: 2026 Outlook, Buffett Exit, Fed Split, Dollar Slide
A/S Genmab Buys 2,978 Shares of Merus (NASDAQ:MRUS) Stock
Market Today: Buffett era ends; Tesla warns; stocks cap strong 2025
First Look: Buffett exits Berkshire (BRK.B); Disney (DIS) pays $10M fine
Market Today: Fed Split, Disney's COPPA Fine, Meta's AI Push
First Look: SoftBank's $4B AI bet, EV reset, silver whipsaws
Merus (NASDAQ:MRUS) Major Shareholder A/S Genmab Buys 15,710 Shares
Merus Sees Unusually Large Options Volume (NASDAQ:MRUS)
Market Today: GDP Jumps, S&P Record; Novo Nordisk (NVO) Pill OK
Market Today: Oracle-TikTok JV, Tesla Pay Reinstated, Nike Sinks
First Look: Oracle leads TikTok JV, CPI cools, Nike drops
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
Merus N.V. $MRUS Shares Acquired by Ensign Peak Advisors Inc